- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04871828
The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19) (PROMISE)
The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19): (Randomized Clinical Trial)
There is an urgent need to explore therapeutic options for SARS-CoV-2 in order to face the pandemic. The selected intervention was based on that zafirlukast will have dual effect; first it will block the virus replication through inhibiting the COVID19 helicase that is involved in virus replication and secondly by reducing the inflammation through antagonizing the leukotriene receptor.
The purpose of this study is to evaluate the clinical efficacy and safety of Leukotriene receptor antagonist in the treatment of moderate cases of COVID-19 patients.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Riyadh, Saudi Arabien, 11426
- Rekruttering
- King Abdulaziz Medical city, MNGHA
-
Kontakt:
- Mohammed Al Ghobain, MD
- Telefonnummer: 14219 009668011111
- E-mail: alghobainmo@NGHA.MED.SA
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age of 18 years or above
- Diagnosed with COVID-19 by PCR confirmed SARS-coV-2 viral infection.
- Able to sign the consent form and agree to clinical samples collection
- Moderate symptomatic COVID-19 patients, (any or all of the followings: fever or cough or SOB)
- Admitted to the hospital (outside the ICU)
- Patients had to be enrolled within 10 days of symptoms onset.
- willingness to comply with all study procedures and availability for the duration of the study
Exclusion Criteria:
- Asthmatic patient using antiasthma medications
- Being in the hospital or in home isolation for more than 72 hours before the start of the study drug.
- Known sensitivity/allergy to the study drug
- Pregnancy
- Patient refused
- Chronic liver disease
- Severe mental disorder
- Unstable patients requiring ICU admission
- Participating in other clinical trial
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Treatment
Zafirlukast plus the standard treatment according to Saudi CDC protocol (combination experimental arm) Description of investigational drug Zafirlukast is leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. It is available as a tablet and is usually dosed twice daily. It is approved by USFDA and currently commercially marketed under the name of Accolate 20 mg oral tablet. The drug will be acquired from the pharmacy and will be received by the patient during the hospital admission via research coordinator. The study drug will be stored in at room temperature (15 - 25 c) in the hospital's pharmacy and a delegated pharmacist will be responsible for dispensing and return of any drugs. The study drug will be administrated to the patient in the dose of 20 mg orally twice daily for 10 days (fixed dose with no staring or escalating dose). |
Zafirlukast
|
Placebo komparator: Control
placebo plus the standard treatment according to Saudi CDC protocol
|
Placebo
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Time to clinical improvement,
Tidsramme: 28Day
|
The time from symptoms resolved: No fever for 72 hours, no cough, no SOB or live discharge from the hospital, whichever came first.
|
28Day
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Escalate therapy.
Tidsramme: 28Day
|
The requirement to escalate therapy.
|
28Day
|
PCR test
Tidsramme: Day14
|
PCR test negative conversion rate at day 14
|
Day14
|
Length of hospital stay.
Tidsramme: 28Day
|
Length of hospital stay.
|
28Day
|
Duration of fever
Tidsramme: 28Day
|
Duration of fever
|
28Day
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Coronavirus infektioner
- Coronaviridae infektioner
- Nidovirales infektioner
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Luftvejsinfektioner
- Luftvejssygdomme
- Lungebetændelse, viral
- Lungebetændelse
- Lungesygdomme
- COVID-19
- Lægemidlers fysiologiske virkninger
- Hormoner, hormonsubstitutter og hormonantagonister
- Anti-astmatiske midler
- Respiratoriske midler
- Hormonantagonister
- Leukotriene-antagonister
Andre undersøgelses-id-numre
- RC20/206/R
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Moderate Covid19
-
University of UtahAfsluttet
-
AbbVieRekrutteringPsoriasis | Moderat plakpsoriasis | Moderat psoriasisGrækenland
-
Beer, Kenneth R., M.D., PAMedicis Pharmaceutical CorporationAfsluttetMild til moderat temporær atrofi | Moderat til svær Glabellar Rhytider | Moderat til svær periorbital rytmeForenede Stater
-
Evergreen General Hospital, TaiwanAfsluttetEndoskopi | Moderat Sedation
-
Children's Hospital of MichiganAfsluttetModerat, dyb sedation
-
National Taiwan University HospitalUkendtKoloskopi | Moderat SedationTaiwan
-
I.M. Sechenov First Moscow State Medical UniversityAfsluttet
-
Derming SRLAfsluttetModerat-alvorlig hudældning/fotografering
-
University Health Network, TorontoAfsluttetModerat svært at intubereCanada
-
Daewoong Pharmaceutical Co. LTD.AfsluttetModerat-alvorlige Glabellar-linjer
Kliniske forsøg med Placebo
-
SamA Pharmaceutical Co., LtdUkendtAkut bronkitis | Akut øvre luftvejsinfektionKorea, Republikken
-
National Institute on Drug Abuse (NIDA)AfsluttetBrug af cannabisForenede Stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAfsluttetMandlige forsøgspersoner med type II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAfsluttetFarmakokinetik | SikkerhedsproblemerDet Forenede Kongerige
-
Texas A&M UniversityNutraboltAfsluttetGlucose and Insulin Response
-
Regado Biosciences, Inc.AfsluttetSund frivilligForenede Stater
-
Longeveron Inc.AfsluttetHypoplastisk venstre hjerte syndromForenede Stater
-
ItalfarmacoAfsluttetBeckers muskeldystrofiHolland, Italien
-
West Penn Allegheny Health SystemAfsluttetAstma | Allergisk rhinitisForenede Stater